Multiple Myeloma Strategies to better predict and improve outcomes in the era of novel anti-myeloma therapies

Multiple myeloma is the second most common haematologic malignancy after non-Hodgkin lymphoma, but despite advances in treatment, remains incurable for most patients. This thesis investigates novel strategies to better predict and improve outcomes in patients with myeloma in the era of novel anti-myeloma therapies, given that there is now focus on developing personalised/targeted therapy approaches. This was through the investigation of consolidation/maintenance strategies following autologous stem cell transplant as part of the up-front treatment for myeloma, investigation of novel anti-myeloma treatments in the relapsed/refractory setting and identification of biomarkers predictive of outcomes to such anti-myeloma treatments.